IGC Share Price | IGC Pharma, Inc. Stock Analysis & Recommendation

Q: How big is IGC Pharma, Inc.?

Market Cap: As of Jun 18, IGC Pharma, Inc. has a market capitalization of 23.91 million, classified as a Micro Cap.Recent Quarterly Performance: For the latest four quarters, IGC Pharma, Inc. reported net sales of 1.23 million and a net profit of -8.81 million.Balance Sheet Snapshot: As of Mar 24, the company reported shareholder's funds of 7.32 million and total assets of 9.90 million.

Q: What does IGC Pharma, Inc. do?

Overview:IGC Pharma, Inc. develops intellectual property for the treatment of life-altering or life-threatening conditions through research on phytocannabinoid-based therapies, operating in the Pharmaceuticals & Biotechnology industry with a micro-cap market classification.Financial Snapshot:Most recent Net Sales: 0 Million (Quarterly Results - Dec 2024)Most recent Net Profit: -2 Million (Quarterly Results - Dec 2024)Market-cap: USD 23.91 Million (Micro Cap)Key Metrics:P/E: NA (Loss Making)Industry P/E: NADividend Yield: 0.00%Debt Equity: -0.03Return on Equity: -129.21%Price to Book: 3.82Contact Details:Address: 10224 FALLS ROAD, POTOMAC MD: 20854Tel: 1 301 9830998Fax: 1 240 4650273Website: http://www.igcinc.us

Q: Is IGC Pharma, Inc. overvalued or undervalued?

As of 10 August 2023, IGC Pharma, Inc. has moved from a grade of does not qualify to risky. The company is overvalued based on its current financial metrics. Key ratios include a Price to Book Value of 3.90, an EV to EBIT of -2.95, and an EV to EBITDA of -3.21, indicating significant operational challenges and a lack of profitability. In comparison, peers such as Equillium, Inc. have an EV to EBITDA of -4.94, and OncoCyte Corp. stands at -2.13, suggesting that IGC Pharma's valuation is less favorable relative to its peers.Despite a strong year-to-date return of 22.59% compared to the S&P 500's 12.22%, the overall long-term performance remains concerning, with a 5-year return of -65.39% versus the S&P 500's 96.61%. This discrepancy highlights the risks associated with investing in IGC Pharma, reinforcing the conclusion that the stock is overvalued.

Q: Is IGC Pharma, Inc. technically bullish or bearish?

As of 2 September 2025, the technical trend for IGC Pharma, Inc. has changed from bullish to mildly bullish. The weekly MACD is bullish, while the monthly MACD is mildly bullish. The daily moving averages indicate a bullish stance, but the weekly RSI is bearish. Bollinger Bands show a mildly bullish trend on both weekly and monthly time frames. The KST is bullish weekly but bearish monthly, and the OBV is bullish monthly with no trend weekly. In terms of performance, IGC Pharma has outperformed the S&P 500 over the past week (1.98% vs. 1.05%) and month (8.37% vs. 2.33%), as well as year-to-date (22.59% vs. 12.22%) and over the past year (21.15% vs. 17.14%). However, it has significantly underperformed over the longer terms of 3 years, 5 years, and 10 years. Overall, the current stance is mildly bullish, with mixed signals from various indicators.

Results Declared: IGC Pharma, Inc. has declared results on 18 Mar 2026! Click here to unlock the latest financial performance

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

221.62 k

Shareholding (Dec 2025)

FII

0.09%

Held by 6 FIIs

DII

98.13%

Held by 2 DIIs

Promoter

0.08%

How big is IGC Pharma, Inc.?

22-Jun-2025

As of Jun 18, IGC Pharma, Inc. has a market capitalization of 23.91 million and reported net sales of 1.23 million with a net profit of -8.81 million over the last four quarters. The company has shareholder's funds of 7.32 million and total assets of 9.90 million as of Mar 24.

View full answer

What does IGC Pharma, Inc. do?

22-Jun-2025

IGC Pharma, Inc. develops phytocannabinoid-based therapies for serious health conditions and operates in the Pharmaceuticals & Biotechnology industry with a market cap of approximately $23.91 million. As of December 2024, the company reported net sales of $0 million and a net loss of $2 million.

View full answer

Who are in the management team of IGC Pharma, Inc.?

22-Jun-2025

As of March 2022, the management team of IGC Pharma, Inc. includes Mr. Richard Prins as the Independent Chairman of the Board and Mr. John Lynch as a Director.

View full answer

Is IGC Pharma, Inc. overvalued or undervalued?

20-Sep-2025

As of August 10, 2023, IGC Pharma, Inc. is considered risky and overvalued due to poor financial metrics, including a Price to Book Value of 3.90 and negative EV ratios, despite a strong year-to-date return of 22.59%, which contrasts sharply with its long-term performance of -65.39% over five years.

View full answer

Is IGC Pharma, Inc. technically bullish or bearish?

20-Sep-2025

As of September 2, 2025, IGC Pharma, Inc. shows a mildly bullish trend with mixed technical indicators, outperforming the S&P 500 in the short term but underperforming over longer periods.

View full answer

Compare IGC Pharma, Inc. with Similar Stocks

Sensei Biotherapeutics, Inc.Forte Biosciences, Inc.Pluri, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 27 Million (Micro Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.12

Return on Equity

-79.66%

Price to Book

3.31

Revenue and Profits:

Net Sales:

0 Million

(Quarterly Results - Dec 2025)

Net Profit:

-1 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-9.14%

6 Months

-30.83%

1 Year

-14.77%

2 Years

-26.78%

3 Years

-20.09%

4 Years

-67.99%

5 Years

-85.04%

IGC Pharma, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

-3.26%

EBIT Growth (5y)

-0.95%

EBIT to Interest (avg)

-10.60

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.03

Sales to Capital Employed (avg)

0.15

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

7.42%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

3.31

EV to EBIT

-3.19

EV to EBITDA

-3.42

EV to Capital Employed

3.63

EV to Sales

23.34

PEG Ratio

Dividend Yield

ROCE (Latest)

-113.89%

ROE (Latest)

-79.66%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

Bearish

RSI

No Signal

Bollinger Bands

Bearish

Mildly Bearish

Moving Averages

Mildly Bearish (Daily)

KST

Mildly Bullish

Dow Theory

No Trend

Mildly Bearish

OBV

No Trend

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Dec 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 2 Schemes (1.7%)

Foreign Institutions

Held by 6 Foreign Institutions (0.09%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Dec 2025 is 0.00% vs 50.00% in Dec 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Dec 2025 is 61.11% vs 67.86% in Dec 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.30",
          "val2": "0.30",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-2.90",
          "val2": "-1.70",
          "chgp": "-70.59%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "2.10",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-0.70",
          "val2": "-1.80",
          "chgp": "61.11%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-8,402.90%",
          "val2": "-7,307.40%",
          "chgp": "-109.55%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Mar'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Mar 2025 is 0.00% vs 44.44% in Mar 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Mar 2025 is 45.38% vs -13.04% in Mar 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Mar'25",
        "Mar'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "1.30",
          "val2": "1.30",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-6.80",
          "val2": "-9.20",
          "chgp": "26.09%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "-3.30",
          "chgp": "100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-7.10",
          "val2": "-13.00",
          "chgp": "45.38%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-5,858.40%",
          "val2": "-7,284.80%",
          "chgp": "142.64%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY

Dec'25

Dec'24

Change(%)

Net Sales

0.30

Operating Profit (PBDIT) excl Other Income

-2.90

-1.70

-70.59%

Interest

0.00

Exceptional Items

2.10

0.00

Consolidate Net Profit

-0.70

-1.80

61.11%

Operating Profit Margin (Excl OI)

-8,402.90%

-7,307.40%

-109.55%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Dec 2025 is 0.00% vs 50.00% in Dec 2024

Consolidated Net Profit

YoY Growth in quarter ended Dec 2025 is 61.11% vs 67.86% in Dec 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Mar'25

Mar'25

Mar'24

Change(%)

Net Sales

1.30

Operating Profit (PBDIT) excl Other Income

-6.80

-9.20

26.09%

Interest

0.00

Exceptional Items

0.00

-3.30

100.00%

Consolidate Net Profit

-7.10

-13.00

45.38%

Operating Profit Margin (Excl OI)

-5,858.40%

-7,284.80%

142.64%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Mar 2025 is 0.00% vs 44.44% in Mar 2024

Consolidated Net Profit

YoY Growth in year ended Mar 2025 is 45.38% vs -13.04% in Mar 2024

All Annual Results

Company CV

About IGC Pharma, Inc.

IGC Pharma, Inc.

Pharmaceuticals & Biotechnology

India Globalization Capital, Inc. develops intellectual property for the treatment of life altering or life threatening conditions, through its research on phytocannabinoid-based therapies, in the United States. The Company also builds farming facilities for leasing. In Malaysia, the Company develops and manages residential and commercial real estate. In India, it leases heavy equipment. It is also focused on developing, testing and patenting phytocannabinoid-based pharmaceutical therapies and becoming a specialty pharmaceutical provider of phytocannabinoid-based pharmaceutical and nutraceutical products. It is developing a product portfolio of phytocannabinoid-based therapies for indications, including neuropathic and cancer pain, epilepsy, end of life supportive care, adjunctive supportive therapies of chronic neurological and oncological diagnosis. In Malaysia, the Company’s subsidiary, Cabaran Ultima Sdn. Bhd., is focused on building a five-star hotel, Genting highlands.

Company Coordinates

Company Details

10224 FALLS ROAD , POTOMAC MD : 20854

Tel: 1 301 9830998

http://www.igcinc.us

Registrar Details